Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023: | | | | | | | | | | | | | (in thousands) | September 30,
2024 | | December 31,
2023 | | Accrued payroll and related expenses | $ | 10,207 | | | $ | 8,807 | | | Accrued clinical expenses | 2,843 | | | 5,063 | | | Accrued manufacturing expenses | 2,452 | | | 2,566 | | | Accrued research, development and non-clinical expenses | 1,879 | | | 3,090 | | | Accrued professional fees | 930 | | | 936 | | | Accrued other | 317 | | | 389 | | | Accrued restructuring expenses | — | | | 1,047 | | | $ | 18,628 | | | $ | 21,898 | |
|